Methyltestosterone

Methyltestosterone

SCHEMBL4575985

C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@@]2(C)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

AR

The experimentally established mechanism targets of Methyltestosterone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR known ✓ P10275 3/20 0.72
SHBG P04278 9/20 1.00
NR3C1 P04150 5/20 1.00
PGR P06401 4/20 1.00
ALDH1A1 P00352 4/20 1.00
ADRA1A P35348 1/20 1.00
HTR2B P41595 1/20 1.00
LMNA P02545 8/20 0.74
SERPINA6 P08185 7/20 0.74
SMN1; SMN2 Q16637 5/20 0.74
BLM P54132 4/20 0.74
CYP2C19 P33261 3/20 0.74
MEN1 O00255 2/20 0.74
KMT2A Q03164 2/20 0.74
MAPT P10636 2/20 0.74
ADORA3 P0DMS8 1/20 0.74
MAPK3 P27361 1/20 0.74
SLC6A3 Q01959 1/20 0.74
TSHR P16473 5/20 0.72
HIF1A Q16665 2/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methyltestosterone SCHEMBL29416593 1.00 SHBG (1.00) SHBGNR3C1PGRALDH1A1ADRA1A
Methyltestosterone SCHEMBL13575766 1.00 SHBG (1.00) SHBGNR3C1PGRALDH1A1ADRA1A
Methyltestosterone SCHEMBL13965283 1.00 SHBG (1.00) SHBGNR3C1PGRALDH1A1ADRA1A
Methyltestosterone SCHEMBL13768123 1.00 SHBG (1.00) SHBGNR3C1PGRALDH1A1ADRA1A
Methyltestosterone SCHEMBL4442874 1.00 SHBG (1.00) SHBGNR3C1PGRALDH1A1ADRA1A
Methyltestosterone SCHEMBL6472960 1.00 SHBG (1.00) SHBGNR3C1PGRALDH1A1ADRA1A
Methyltestosterone SCHEMBL18657 1.00 SHBG (1.00) SHBGNR3C1PGRALDH1A1ADRA1A
Methyltestosterone SCHEMBL18891626 1.00 SHBG (1.00) SHBGNR3C1PGRALDH1A1ADRA1A
Methyltestosterone SCHEMBL5021655 1.00 SHBG (1.00) SHBGNR3C1PGRALDH1A1ADRA1A
Methyltestosterone SCHEMBL6152059 1.00 SHBG (1.00) SHBGNR3C1PGRALDH1A1ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030119796-A1 Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women SCHERING CORPORATION 2003-06-26 US claimed
CN-1026001-C New esters of alginic acid FIDIA SPA (IT) 1994-09-28 CN claimed
CN-87104499-A Novel alginic acid esters 1988-04-06 CN claimed
CN-118006798-A Preparation method and application of all-female grass carp parent 中国科学院水生生物研究所 2024-05-10 CN disclosed
CN-116429952-B Depression marker, application thereof in depression diagnosis and evaluation device 深圳市第二人民医院(深圳市转化医学研究院) 2024-02-02 CN disclosed
US-20230242984-A1 SEX DETERMINATION MARKERS IN MULLETS AND METHODS OF USING THEREOF THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI INSTITUTE] (IL) 2023-08-03 US disclosed
CN-116429952-A Depression marker, application thereof in depression diagnosis and evaluation device 深圳市第二人民医院(深圳市转化医学研究院) 2023-07-14 CN disclosed
CN-116347978-A Sex determination markers in mullet and methods of use thereof 以色列国家农业部·农村发展农业研究组织·沃尔卡尼机构 2023-06-27 CN disclosed
US-11541062-B2 Methods of treating advanced prostate cancer CITY OF HOPE (US) 2023-01-03 US disclosed
US-11536733-B2 Methods and systems for the detection of 11-oxo androgens by LC-MS/MS LABORATORY CORPORATION OF AMERICA HOLDINGS (US) 2022-12-27 US disclosed
US-20200333361-A1 Methods and Systems for the Detection of 11-Oxo Androgens by LC-MS/MS LABORATORY CORPORATION OF AMERICA HOLDINGS 2020-10-22 US disclosed
CN-104230031-A Method for extracting multicomponent drugs and personal care products in surface water RES CT ECO ENVIRONMENTAL SCIEN 2014-12-24 CN disclosed
US-7422854-B1 Cholesterol reduction signature ENTELOS, INC. (US) 2008-09-09 US disclosed
US-20060199793-A1 Sterol absorption inhibitor compounds CHO WING-KEE P 2006-09-07 US disclosed
CN-1026001-C New esters of alginic acid FIDIA SPA (IT) 1994-09-28 CN disclosed
CN-1092287-A Discharge and its implementation with variable dose rate control medicine percutaneous UNIV RUTGERS (US) 1994-09-21 CN disclosed
CN-1025035-C Cross-linked esters of hyaluronic acid FIDIA SPA (IT) 1994-06-15 CN disclosed
CN-87106919-A CROSS-LINKED ESTERS OF HYALURONIC ACID 1988-08-24 CN disclosed
CN-87104499-A Novel alginic acid esters 1988-04-06 CN disclosed
US-4160027-A OXYTOCICS, 4A,5A-EPOXY-2A-CYANO-3-OXOSTEROIDES, STEROIDO(2,3-O)ISOOXAZOLES STERLING DRUG INC. (US) 1979-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119796-A1 Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women SHBG, CYP46A1, HSD3B1 AR 914/4885SHBG 1/4885NR3C1 334/4885
US-20060199793-A1 Sterol absorption inhibitor compounds SREBF1, CYP46A1, FABP2 AR 531/4885SHBG 61/4885NR3C1 675/4885
US-11541062-B2 Methods of treating advanced prostate cancer KLK3, AR, ACP3 AR 2/4885SHBG 4/4885NR3C1 158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.